Occipital Nerve Stimulation Effective for Chronic Migraine

Share this content:
Occipital Nerve Stimulation Effective for Chronic Migraine
Occipital Nerve Stimulation Effective for Chronic Migraine

FRIDAY, Oct. 28, 2016 (HealthDay News) -- For patients with chronic migraine (CM), peripheral nerve stimulation of the occipital nerves reduces the number of headache days, according to a study published online Oct. 25 in Pain Practice.

Nagy A. Mekhail, M.D., Ph.D., from the Cleveland Clinic, and colleagues implanted 20 patients at a single center with a neurostimulation system, and randomized them to an active or control group for 12 weeks. Patients received open-label treatment for an additional 40 weeks.

The researchers observed a reduction in the number of headache days per month (8.51 days; P < 0.0001). Sixty and 35 percent of patients achieved a 30 and 50 percent reduction, respectively, in headache days and/or pain intensity. All patients had reductions in Migraine Disability Assessment and Zung Pain and Distress scores. At least one adverse event was reported by 15 of the patients, with a total of 20 adverse events reported.

"Our results support the 12-month efficacy of 20 CM patients receiving peripheral nerve stimulation of the occipital nerves in this single-center trial," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »